The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Issues and progress with protein kinase inhibitors for cancer treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Protein kinase Cα activates RAF-1 by direct phosphorylation
Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marmé, D., & Rapp, U. R. (1993) · Nature · doi:10.1038/364249a0 · Cited by 1,277
FAK integrates growth-factor and integrin signals to promote cell migration
Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H., & Schlaepfer, D. D. (2000) · Nature Cell Biology · doi:10.1038/35010517 · Cited by 1,240
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello, F., & Tortora, G. (2001) · PubMed · Cited by 977
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T. H., Veach, D. R., Miller, W. T., Clarkson, B. D., & Kuriyan, J. (2002) · PubMed · Cited by 923
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Fluorescence molecular tomography resolves protease activity in vivo
Ntziachristos, V., Tung, C.-H., Bremer, C., & Weissleder, R. (2002) · Nature Medicine · doi:10.1038/nm729 · Cited by 827
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Scatter-factor and semaphorin receptors: cell signalling for invasive growth
Trusolino, L., & Comoglio, P. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc779 · Cited by 745
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
Linkage of G Protein-Coupled Receptors to the MAPK Signaling Pathway Through PI 3-Kinase γ
Lopez-Ilasaca, M., Crespo, P., Pellici, P. G., Gutkind, J. S., & Wetzker, R. (1997) · Science · doi:10.1126/science.275.5298.394 · Cited by 670
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.051 · Cited by 610
Herbst, R. S., Maddox, A.-M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Management of malignant gastrointestinal stromal tumours
Joensuu, H., Fletcher, C., Dimitrijevic, S., Silberman, S., Roberts, P., & Demetri, G. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00899-9 · Cited by 567
Huang, S., & Harari, P. M. (2000) · PubMed · Cited by 555
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R. S., LoRusso, P. M., Rischin, D., Sauleda, S., Gee, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.110 · Cited by 528
Chakravarti, A., Loeffler, J. S., & Dyson, N. J. (2002) · PubMed · Cited by 509
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.
Milas, L., Mason, K. A., Hunter, N. R., et al. (2000) · PubMed · Cited by 503
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis
Yamada, K. M., & Araki, M. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2375 · Cited by 479
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
Fan, Z., Baselga, J., Masui, H., et al. (1993) · PubMed · Cited by 431
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Targeting the epidermal growth factor receptor for cancer therapy.
Mendelsohn, J. M. (2002) · PubMed · Cited by 414
Rubin, B. P., Schuetze, S. M., Eary, J. F., Norwood, T. H., Mirza, S. K., Conrad, E. U., & Bruckner, J. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.027 · Cited by 364
Activity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351
The TOR Kinases Link Nutrient Sensing to Cell Growth
Rohde, J., Heitman, J., & Cardenas, M. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r000034200 · Cited by 351
Development of anticancer drugs targeting the MAP kinase pathway
Sebolt-Leopold, J. S. (2000) · Oncogene · doi:10.1038/sj.onc.1204083 · Cited by 320
A p34cdc2 survival checkpoint in cancer
O'Connor, D. S., Wall, N. R., Porter, A. C. G., & Altieri, D. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00084-3 · Cited by 315
Ras and Rho regulation of the cell cycle and oncogenesis
Pruitt, K., & Der, C. J. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00528-6 · Cited by 311
Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., & Houghton, P. J. (1999) · PubMed · Cited by 310
Progress in understanding the molecular pathogenesis of human lung cancer
Sekido, Y., Fong, K. M., & Minna, J. D. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00010-9 · Cited by 290
Wilhelm, S., & Chien, D.-S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393026 · Cited by 289
Kuenen, B. C., Rosen, L. S., Smit, E. F., Parson, M., Levi, M. M., Ruijter, R., Huisman, H., Kedde, M. A., Noordhuis, P., van der Vijgh, W. J. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1657 · Cited by 279
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Geoerger, B., Kerr, K., Tang, C. B., Fung, K., Powell, B., Sutton, L. N., Phillips∥, P. C., & Janss, A. J. (2001) · PubMed · Cited by 261
Cell cycle targets of Ras/Raf signalling
Kerkhoff, E., & Rapp, U. R. (1998) · Oncogene · doi:10.1038/sj.onc.1202185 · Cited by 260
Molecular mechanisms for the control of translation by insulin
PROUD, G. C., & DENTON, M. R. (1997) · Biochemical Journal · doi:10.1042/bj3280329 · Cited by 257
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis.
Wall, N. R., O’Connor, D. S., Plescia, J., Pommier, Y. G., & Altieri, D. C. (2003) · PubMed · Cited by 252
Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M. G., Arbuck, S. G., Travis, R., Sausville, E. A., & Houghton, P. J. (2001) · PubMed · Cited by 232
Self-citationRapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., & Mills, G. B. (1995) · PubMed · Cited by 225
Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
Scappaticci, F. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.033 · Cited by 225
Majewski, M., Korecka, M., Kossev, P., Li, S., Goldman, J., Moore, J., Silberstein, L. E., Nowell, P. C., Schuler, W., Shaw, L. M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080068597 · Cited by 210
Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. T. W. (1999) · PubMed · Cited by 209
New antitumor substances of natural origin
Douros, J., & Suffness, M. (1981) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(81)80006-0 · Cited by 202
Seimiya, H., Mashima, T., Toho, M., & Tsuruo, T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4631 · Cited by 201
Chemoprevention of Breast Cancer: A Model for Change
Jordan, V. C., & Morrow, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.1 · Cited by 197
Catling, A. D., Schaeffer, H.-J., Reuter, C. W. M., Reddy, G. R., & Weber, M. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5214 · Cited by 196
PI3-kinase inhibition: a target for drug development?
Stein, R. C., & Waterfield, M. D. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01770-6 · Cited by 192
Perez-Soler, R. (2001) · Medical Entomology and Zoology · Cited by 189
Targeting the epidermal growth factor receptor
El-Rayes, B. F., & LoRusso, P. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601921 · Cited by 184
p38 and Chk1 kinases: different conductors for the G2/M checkpoint symphony
Bulavin, D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00270-2 · Cited by 172
Studies on the Mechanism of Resistance to Rapamycin in Human Cancer Cells
Hosoi, H., Dilling, M. B., Liu, L. N., Danks, M. K., Shikata, T., Sekulic, A., Abraham, R. T., Lawrence, J. C., & Houghton, P. J. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.5.815 · Cited by 172
Seufferlein, T., & Rozengurt, E. (1996) · PubMed · Cited by 169
Webb, C. P., Hose, C. D., Koochekpour, S., Jeffers, M., Oskarsson, M. K., Sausville, E. A., Monks, A. P., & Woude, G. F. V. (2000) · PubMed · Cited by 168
Self-citationInfluence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials
Betensky, R. A., Louis, D. N., & Gregory Cairncross, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.140 · Cited by 167
Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., & Grant, S. (2001) · PubMed · Cited by 158
New Insights into the Interaction of Ras with the Plasma Membrane
Magee, T., & Marshall, C. (1999) · Cell · doi:10.1016/s0092-8674(00)80601-7 · Cited by 158
RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS
Muthukkumar, S., Ramesh, T., & Bondada, S. (1995) · Transplantation · doi:10.1097/00007890-199508000-00010 · Cited by 142
Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.
Stein, R. C. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080237 · Cited by 131
Huang, S., Liu, L. N., Hosoi, H., Dilling, M. B., Shikata, T., & Houghton, P. J. (2001) · PubMed · Cited by 130
Stevenson, J. P., Yao, K.-S., Gallagher, M., Friedland, D. P., Mitchell, E. P., Cassella, A., Monia, B. P., Kwoh, T. J., Yu, R. Z., Holmlund, J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2227 · Cited by 129
Lynch, D. H., & Yang, X. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31522 · Cited by 128
Cunningham, C. C., Holmlund, J., Schiller, J. H., Geary, R. S., Kwoh, T. J., Dorr, A., & Nemunaitis, J. J. (2000) · PubMed · Cited by 126
Novel Small Molecule Cyclin-Dependent Kinases Modulators in Human Clinical Trials
Senderowicz, A. M. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.207 · Cited by 121
Tolcher, A. W., Reyno, L. M., Venner, P. M., Ernst, S., Moore, M. J., Geary, R. S., Chi, K., Hall, S. R. R., Walsh, W., Dorr, A., et al. (2002) · PubMed · Cited by 119
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
Druker, B. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206081 · Cited by 116
Cornwell, M. M., & Smith, D. E. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82262-1 · Cited by 107
Strumberg, D., Voliotis, D., Moeller, J.-G., Hilger, R. A., Richly, H., Kredtke, S., Beling, C., Scheulen, M. E., & Seeber, S. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40580 · Cited by 104
Cripps, M. C., Figueredo, A. T., Oza, A. M., Taylor, M. J., Fields, A. L. A., Holmlund, J. T., McIntosh, L., Geary, R. S., & Eisenhauer, E. A. (2002) · PubMed · Cited by 96
Activation of Human raf Transforming Genes by Deletion of Normal Amino-Terminal Coding Sequences
Stanton, V. P., & Cooper, G. M. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.3.1171 · Cited by 96
Therapies directed at vascular endothelial growth factor
Manley, P. W., Martiny‐Baron, G., Schlaeppi, J.-M., & Wood, J. M. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1715 · Cited by 92
Bishop, P. C., Myers, T. G., Robey, R. W., Fry, D. W., Liu, E. T., Blagosklonny, M. V., & Bates, S. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205028 · Cited by 84
Coudert, B. P., Anthoney, A., Fiedler, W., Droz, J., Dieras, V. C., Borner, M., Smyth, J. F., Morant, R., de Vries, M. J., Roelvink, M., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00286-6 · Cited by 83
[29] Inhibition of protein-tyrosine kinases by tyrphostins
Levitzki, A., Gazit, A., Osherov, N., et al. (1991) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(91)01031-v · Cited by 76
UCN-01 Enhances the In Vitro Toxicity of Clinical Agents in Human Tumor Cell Lines
Monks, A. P., Harris, E. D., Vaigro-Wolff, A., Hose, C. D., Connelly, J. W., & Sausville, E. A. (2000) · Investigational New Drugs · doi:10.1023/a:1006313611677 · Cited by 73
Self-citationDrug inhibition of angiogenesis
Madhusudan, S., & Harris, A. L. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00184-4 · Cited by 72
Molecular diagnosis of lymphoid malignancies by gene expression profiling
Davis, R. E., & Staudt, L. M. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00011 · Cited by 67
Rosato, R. R., Almenara, J. A., Cartee, L., Betts, V., Chellappan, S., & Grant, S. (2002) · PubMed · Cited by 66
Abrogation of c-Raf expression induces apoptosis in tumor cells
Lau, Q. C., Brüsselbach, S., & Müller, R. (1998) · Oncogene · doi:10.1038/sj.onc.1201709 · Cited by 65
Nahta, R., Iglehart, J. D., Kempkes, B., & Schmidt, E. V. (2002) · PubMed · Cited by 48
Ferron, G. M., & Jusko, W. J. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37575-5 · Cited by 46
Hambek, M., Solbach, C., Schnuerch, H. G., Roller, M., Stegmueller, M., Sterner‐Kock, A., Kiefer, J., & Knecht, R. (2001) · PubMed · Cited by 45
The Ras-Raf relationship: an unfinished puzzle
Kerkhoff, E., & Rapp, U. R. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00023-6 · Cited by 41
Cell Biology of Lymphatic Metastasis The Potential Role of c-erbB Oncogene Signalling
Eccles, S. A. (2000) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-57151-0_5 · Cited by 40
Ferron, G. M., Pyszczynski, N. A., & Jusko, W. J. (1998) · Transplantation · doi:10.1097/00007890-199805150-00011 · Cited by 33
Cell Cycle Progression and Proliferation Despite 4BP-1 Dephosphorylation
Marx, S. O., & Marks, A. R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6041 · Cited by 29
Wang, S., Wang, Z., & Grant, S. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.1.232 · Cited by 24
Cartee, L., Maggio, S. C., Smith, R. L., Sankala, H. M., Dent, P., & Grant, S. (2003) · PubMed · Cited by 21
Role of GTPases and GTPase regulatory proteins in oncogenesis.
Grunicke, H. H., & Maly, K. (1993) · PubMed · Cited by 21
Swaisland, H., Smith, R. S., Jones, H., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)80728-0 · Cited by 6
Cited by
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Metadata
- Authors
- Dancey, J., & Sausville, E. A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-04-01
- Volume
- 2
- Issue
- 4
- Pages
- 296-313
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1993860023
- Cited by
- 526
- References
- 113
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.